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for 40% of decisions, were compared with those of three major HTA agencies: CADTH, 
NICE and PBAC. HTA reports and meeting transcripts were analysed and categorised 
by date, therapy area, decision, rationale, and pricing decision. Resubmissions or those 
not assessed by the western HTA agencies were excluded. Results: A total of 65 NHI 
reports were identified. Of these 26 reported decisions on oncology or cardiovascular 
drugs, 12 were excluded (3 resubmissions, 9 not reviewed by the other agencies). Prior 
to 2GNHI, 4 out of 5 decisions were positive, or 80% approval rate, while after, only 
4 out of 9 were positive, a 44% approval rate. Prior to 2GNHI, all NHI reimbursement 
decisions identified (6) matched CADTH, NICE, and PBAC. After 2GNHI, only 6/9 or 
66% matched. Clinical effectiveness and budget impact were most cited in reim-
bursement rejections. For example Zytiga, NHI appreciated the cost-effectiveness 
but stated budget impact was too high, issuing a negative recommendation, contrary 
to the other agencies. Interestingly, a ‘local’ product was recommended for limited 
reimbursement even though budget impact was high. ConClusions: Since imple-
mentation of Taiwan’s NHI reforms in January 2013, cardiovascular and oncology drug 
approvals dropped by 36% and agreements with western agencies down 34%, placing 
an emphasis on budget impact. However, this analysis was constrained by its small 
sample size, and limited therapy areas.
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objeCtives: Phase III, randomised controlled trials remain the gold standard 
for health technology assessment (HTA) submissions. Data sets may be sup-
plemented with other sources (e.g. Phase II trials, observational studies, mixed 
treatment comparisons). However, the influence of expanded data sets on HTA 
appraisals is unclear. Methods: We reviewed recent National Institute for 
Health and Care Excellence (NICE; England and Wales) oncology drug submissions 
to determine the frequency and type of expanded data sets. We then evaluated 
the influence of expanded data on agency decisions. A similar review of submis-
sions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC) was 
performed. Results: There were 30 relevant appraisals on the NICE website 
covering a range of cancer types. Of these, 14/30 made use of expanded data sets 
featuring Phase II trials, observational studies, meta-analyses and/or mixed treat-
ment comparisons among other sources. Reasons for using expanded data sets 
included: agency concerns over Phase III studies, lack of long-term or head-to-head 
data and limited Phase III data. Where additional data were included, around one 
third (5/14 cases, 35.7%; 5/30 [16.7%] overall) appeared to have directly influenced 
the final decision. Overall, positive appraisals were less frequent for submissions 
that featured expanded data sets compared with submissions featuring Phase III 
data only (2/14 [14.3%] versus 9/16 [56.3%]). Comparable to NICE, 2/10 (20%) of PBAC 
submissions were influence by expanded data sets, although cost-effectiveness data 
were crucial for PBAC approval overall. ConClusions: We found that expanded 
data sets feature in nearly half of recent NICE oncology HTA assessments. However, 
additional data appeared to influence only one in five appraisals by NICE and PBAC. 
Expanded data sets have a place in contributing to HTA decision making, but overall, 
rigorous Phase III RCT data remain essential to obtaining a positive HTA appraisal.
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objeCtives: Since January 2009, NICE in the UK allows end of life (EOL) treatments 
to exceed the upper end (£30,000/QALY) of the threshold range for incremental 
cost-effectiveness ratios (ICERs) by using higher weights for EOL life-years. With 
discussions surrounding the concept and implementation, and the introduction of 
the value based assessment framework, the aim of this study was to review NICE 
technology appraisals (TAs) in oncology to assess the interpretation, implementa-
tion and implications of the criteria. Methods: All completed TAs in oncology 
since 2009 were searched. When multiple submissions of the same TA were made, 
the latest were selected. Data were extracted to capture details of the appraisal 
(e.g. treatment, indication and decision), the consideration of the five different 
EOL criteria (applicability, interpretation, effect on the decision) and the method 
of implementation (weighting, threshold). Results: 61 TAs, including six multi-
ple technology appraisals, assessing 71 technologies were reviewed. EOL criteria 
were considered in 40 TAs covering 44 technologies. EOL weighting was considered 
appropriate for 36% of technologies. Most technologies fulfilled the criterion of 
< 24 month life expectancy (rejected in 14%), extension of life by ≥ 3 months or 
robustness of its calculation was the most common cause of rejection (32%/25% 
respectively). These criteria were inconsistently applied, using different methods 
(e.g. medians, restricted means from extrapolation, means from trial or model). The 
criterion of small population favoured technologies with limited indication (rejec-
tion 20%). Earlier TAs presented weight calculations, while later TAs only presented 
ICERs. ConClusions: Although aiming for greater transparency, the criteria left 
a large scope for interpretation in the decision making. Also, with the emphasis 
from applying higher weights to EOL life-years shifting to a differential threshold 
for certain indications, the original idea of considering wider societal preferences 
seem to have been neglected, that the new guidance should remedy.
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be issued a “do not recommend” decision than non-oncology reviews (56% vs. 16%, 
p< . 001). Over time, there was no significant trend in rates of “do not recommend” 
decisions for non-oncology reviews and oncology reviews, though rates of “do not 
recommend” decisions have increased for oncology reviews since 2008. There were no 
differences in the rates of “recommend” and “recommend with restriction” decisions 
between oncology and non-oncology reviews (p= . 87). Over time there was a signifi-
cant decrease in the rates of “recommend with restrictions” decisions for oncology 
reviews (p= . 07), but no statistical trend in non-oncology reviews. ConClusions: 
NICE was more likely to issue a “do not recommend” decision for oncology reviews 
than for non-oncology reviews, but there was no difference in the overall rates of 
“recommend with restrictions” decisions. Over time, NICE appears to be replacing 
“recommend with restriction” decisions with “do not recommend” decisions in oncol-
ogy reviews, but this did not pass traditional significance levels.
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Nowadays, economic evaluation has been increasingly used in health care decision-
making in Brazil. The Brazilian economic evaluation literature in cancerology is 
unknown. objeCtives: This systematic review aims to identify and characterize 
the economic evaluation studies in cancerology conducted in Brazil. Methods: 
Ten online databases (MEDLINE (PubMed), EMBASE, Latin American and Caribbean 
Literature on Health Sciences Database (LILACS), Scientific Electronic Library Online 
(SciELO), NHS Economic Evaluation Database (NHS EED), HTA Database (Centre 
for Reviews and Dissemination (CRD)), Biblioteca Virtual em Saúde Economia da 
Saúde (BVS ECOS), SCOPUS, Web of Science, and the Sistema de Informação da Rede 
Brasileira de Avaliação de Tecnologias em Saúde (SISREBRATS) were systematically 
searched. We also performed manual search. We selected partial and full economic 
evaluation studies in cancerology, where at least one of the authors was affiliated 
to a Brazilian institution. Two authors performed study selection and data extrac-
tion independently. Disagreements were resolved through discussion or through 
consultation with a third reviewer. The study characteristics were summarized in 
figures and summary tables. Results: A total of 11946 records were identified. Fifty 
six articles met inclusion criteria, of these, 33 (59%) were a full and 23 (41%) were 
a partial economic evaluation. The cost-effectiveness analysis was the most used 
(27%). There was an increase in the number of publications over the years, especially 
after 2006. Researchers from the Southeast region of Brazil were responsible for the 
majority of the publications (82%). Cancers most frequently studied were breast can-
cer (37%), followed by cervical cancer (16%), lung cancer (12%) and colorectal cancer 
(9.0%). The technologies most studied were medications (34%). ConClusions: The 
expansion of the economic analysis literature could be explained by the growing 
demand for HTA studies by the National Policy for Health Technology Assessment 
in Brazil that may have stimulated the scientific production in this area.
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objeCtives: Crizotinib (Xalkori®) was approved for the treatment of adults with 
non-small cell lung cancer (NSCLC). The objective of this study was to illustrate the 
divergence of Health Technology Assessments in oncology by comparing the deci-
sions of the National Institute for Health and Care Excellence (NICE), the Federal 
Joint Committee (G-BA) and French National Authority for Health (HAS). Methods: 
Crizotinib’s pivotal trial (Study 1007) was analysed. NICE, G-BA and HAS reports 
were reviewed, decisions’ drivers identified and final decisions compared. Results: 
Study 1007 was a randomised open-label trial comparing crizotinib with chemo-
therapy in patients with ALK+ advanced NSCLC and who had failed one chemo-
therapy regimen. The primary endpoint was progression-free survival (PFS) and 
overall survival (OS) was a secondary endpoint. While treatment with crizotinib 
increased significantly the PFS (4.7 months) no significant improvement in OS was 
observed versus chemotherapy group (OS interim analysis). Some quality of life 
(QoL) items (e.g. chest pain, dyspnea, fatigue) were improved within the crizotinib 
group. Even though no improvement in the OS was shown, the G-BA assessed the 
crizotinib benefit as considerable based on the improvement of QoL and morbidity 
decrease. The HAS also granted crizotinib an improvement in actual benefit of III 
based on the improvements in the PFS and QoL. However, the significant gain in PFS 
was not sufficient to get positive guidance from NICE. Indeed, NICE did not recom-
mend the use of crizotinib due to the uncertainties surrounding the OS: interim OS 
data and high rate of patients “crossing-over” from standard therapy to crizotinib 
arm. ConClusions: Cross-over has become a real obstacle to appreciate oncology 
product value. While an additional benefit can be granted based on improvement 
in PFS plus morbidity and QoL results in Germany and France, products supported 
solely by an increased PFS and no change in OS may face access barriers in England.
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objeCtives: Taiwan is considered a challenging market to access, largely due to strict 
pricing and reimbursement policies. To assess the impact of health insurance reforms 
introduced in January 2013 (Second Generation National Health Insurance or 2GNHI), 
Taiwan reimbursement decisions and granted prices before and after the introduction 
were compared with major western countries. Methods: Publications of Taiwan 
NHI from March 2011 to February 2014 were searched and reimbursement decisions 
identified. The largest therapy areas, oncology and cardiovascular, which accounted 
